drugset / Trial / NCT02639182
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study was to evaluate the progression free survival (PFS), based on investigator radiologic review, of AGS-16C3F compared to axitinib in subjects with metastatic renal cell carcinoma.
Timeline
- Start
- 2016-05-03
- Primary completion
- 2020-10-02
- Completion
- 2020-10-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AGS-16C3F | Unknown | 1.8 mg/kg | Intravenous |
| Comparator | Axitinib | Small molecule | 2 mg | Oral |
| Comparator | Axitinib | Small molecule | 10 mg | Oral |